Tarsus Pharmaceuticals Inc Up 10.28% To $17.17 After Earnings Beat

Friday, November 10, 2023 - Tarsus Pharmaceuticals Inc (TARS) reported upside earnings and revenues today.

The consensus among analysts for Tarsus Pharmaceuticals Inc was for an earnings per share (EPS) loss of $1.36 per share. The firm was able to surpass those projections, reporting an EPS loss of $1.28 per share, a positive surprise of $0.08 (6%). Profits fell 52% year-over-year after reporting an EPS loss of $0.84 per share in its year-ago quarter. The negative growth rate signals that the Healthcare company isn't performing well amid current economic conditions.

Consensus estimates for Tarsus Pharmaceuticals Inc revenue averaged out to $400 thousand, with the business managing to beat those expectations with reported third-quarter revenue of $1.9 million. The $1.5 million (368%) positive revenue surprise led to 0% growth year-over-year as the firm reported revenue of $0.00 in its year-ago quarter. The lower earnings growth compared to revenue points to Tarsus Pharmaceuticals Inc not being able to improve its profit margin.

The stock is up 10.28% to $17.17 after the report.

The firm's higher revenue growth to earnings signals that the firm has not been able to reduce costs and has seen its profit margin decrease.

The average recommendation from Wall Street analysts was a Strong Buy which may get revised based on this new data.

Trading in the five days leading up to the report earned Tarsus Pharmaceuticals Inc a Bearish Sentiment Rank from InvestorsObserver.

Tarsus Pharmaceuticals Inc has performed a little below average during the past few months. Before the report, Tarsus Pharmaceuticals Inc received a Long-Term Technical Rank by InvestorsObserver of 37, putting it in the bottom half of stocks. The firm set a 52-week high on July 24, 2023 at $25.25 and set a 52-week low on April 17, 2023 at $11.33.

Tarsus Pharmaceuticals Inc is a late clinical-stage biopharmaceutical company. It is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's lead candidate TP-03, is a novel drug that targets the Demodex mite nervous system to kill the mites.